Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the efficacy and toxicity of docetaxel (TAX), cisplatin (CDDP), and fluorouracil (5-FU) plus leucovorin (CF) as the neoadjuvant chemotherapy (NACT) regimens in the treatment of nonresectable advanced gastric cancer. Twelve patients with nonresectable advanced gastric cancer were treated with NACT regimens consisted of docetaxel, cisplatin, fluorouracil, plus leucovorin before operation. Nine of the 12 patients were downstaged and 8 were radically operated after the end of the NACT. The overall response rate was 75% with 8.3% complete response and 66.7% partial response, and the ascites disappeared in 63.6%. The most common toxicities were bone marrow suppression, nausea, vomiting, alopecia, and heptoses. The toxicities were recoverable after symptomatic treatment. The results confirmed that the combination of docetaxel, cisplatin, fluorouracil plus leucovorin (CF) is a very effective and well-tolerated regimen as NACT for the patients with nonresectable advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. Blanke CD, Corless CL, Schwarz RE, et al. Gastric cancer. 9th ed. Lawrence, KS: CMP Healthcare Media; 2005.

    Google Scholar 

  3. Hazard L, O’Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol. 2006;12:1511–20.

    PubMed  Google Scholar 

  4. Chadha MK, Kuvshinoff BW, Javle MM. Neoadjuvant therapy for gastric cancer. Oncology (Williston Park). 2005;19:1219–27. discussion 27–8, 31–2.

    Google Scholar 

  5. Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88:21–7.

    CAS  PubMed  Google Scholar 

  6. Falcone A. Future strategies and adjuvant treatment of gastric cancer. Ann Oncol. 2003;14(Suppl 2):45–7.

    Google Scholar 

  7. Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a Phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol. 1989;7:1318–26.

    CAS  PubMed  Google Scholar 

  8. Plukker JT, Mulder NH, Sleijfer DT, et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5-fluorouracil. Br J Surg. 1991;78:955–8.

    Article  CAS  PubMed  Google Scholar 

  9. Ajani JA, Ota DM, Jessup JM, et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991;68:1501–6.

    Article  CAS  PubMed  Google Scholar 

  10. Lowy AM, Mansfield PF, Leach SD, et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.

    Article  CAS  PubMed  Google Scholar 

  11. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80:269–72.

    Article  CAS  PubMed  Google Scholar 

  12. Schuhmacher CP, Fink U, Becker K, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer. 2001;91:918–27.

    Article  CAS  PubMed  Google Scholar 

  13. Niederhuber JE. Neoadjuvant therapy. Ann Surg. 1999;229:309–12.

    Article  CAS  PubMed  Google Scholar 

  14. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol. 2005;23(Suppl 16):4001.

    Google Scholar 

  15. Siewert JR, Stein HJ, von Rahden BH. Multimodal treatment of gastrointestinal tract tumors: consequences for surgery. World J Surg. 2005;29:940–8.

    Article  PubMed  Google Scholar 

  16. Yonemura Y, Kinoshita K, Fujimura T, et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology. 1996;43:1260–72.

    CAS  PubMed  Google Scholar 

  17. Becker K, Mueller JD, Schuhmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.

    Article  PubMed  Google Scholar 

  18. Kodera Y, Sasako M, Yamamoto S, et al. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg. 2005;92:1103–9.

    Article  CAS  PubMed  Google Scholar 

  19. Degiuli M, Sasako M, Ponti A, et al. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer. 2004;4:1727–32.

    Google Scholar 

  20. Edwards P, Blackshaw GR, Lewis WG, et al. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer. 2004;17:1888–92.

    Article  Google Scholar 

  21. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;25:908–14.

    Article  Google Scholar 

  22. Sakamoto J. Neoadjuvant chemotherapy: a standard treatment for locally advanced gastric cancer in the near future? Gastric Cancer. 2003;6:131–3.

    Article  PubMed  Google Scholar 

  23. Ozdemir NY, Abali H, Oksüzoğlu B, Budakoglu B, Uncu D, Güler T, Odabaşı H, Zengin N. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol. 2009 [Epub ahead of print].

  24. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.

    Article  PubMed  CAS  Google Scholar 

  25. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205–9.

    Article  CAS  PubMed  Google Scholar 

  26. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673–9.

    Article  CAS  PubMed  Google Scholar 

  27. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7.

    Article  CAS  PubMed  Google Scholar 

  28. Hohler T, Moehler M. New chemotherapeutic options in advanced gastric cancer (in German). Onkologie. 2003;26(Suppl 7):54–9.

    Article  PubMed  Google Scholar 

  29. Haller DG, Misset JL. Docetaxel in advanced gastric cancer. Anticancer Drugs. 2002;13:451–60.

    Article  CAS  PubMed  Google Scholar 

  30. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology. 2002;16:89–96.

    PubMed  Google Scholar 

  31. Kohne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology. 2000;14:22–5.

    CAS  PubMed  Google Scholar 

  32. Moehler M, Schimanski CC, Gockel I, et al. (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis. 2004;22:345–50.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, 600 Yishan Road, Shanghai, 200233, People’s Republic of China

    Yanlei Ma, Huanlong Qin, Qi Zheng, Yu Wang, Zhiguo Wang & Zhe Yang

Authors
  1. Yanlei Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huanlong Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiguo Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhe Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhe Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ma, Y., Qin, H., Zheng, Q. et al. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication. Med Oncol 27, 1089–1095 (2010). https://doi.org/10.1007/s12032-009-9340-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9340-7

Keywords

Search

Navigation